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Abstract
Purpose of review—The authors present evidence published during the past two years of the
roles of commensal and pathogenic bacteria in the pathogenesis of the inflammatory bowel
diseases (IBD).
Recent findings—Rodent models conclusively implicate commensal enteric bacteria in chronic,
immune-mediated, experimental colitis, and genetically determined defects in bacterial killing by
innate immune cells are found in a subset of Crohn’s disease patients. There is no evidence that a
single pathogen, including Mycobacterium avium subspecies paratuberculosis, causes Crohn’s
disease or ulcerative colitis. However, adherent/invasive E. coli (AIEC) are associated with ileal
Crohn’s disease, with the mechanisms and genetics of AIEC virulence being elucidated.
Molecular characterization of the microbiota in patients with IBD reveals decreased biodiversity
of commensal bacteria, most notably the phyla Bacteroidetes and Firmicutes, including the
clinically-relevant Faecalibacterium prausnitzii, and increased E. coli concentrations. VSL#3 is
one probiotic preparation shown to be efficacious in certain clinical situations in small clinical
trials.
Summary—Further characterization of altered microbiota in patients with IBD and linking
dysbiosis with host genetic alterations in immunoregulation, innate microbial killing and barrier
function are critical, so that individualized treatments to increase beneficial commensals and their
metabolic products (probiotic and prebiotic administration) and diminish deleterious species such
as AIEC can be tailored for defined patient subsets.
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Introduction
Chronic idiopathic inflammatory bowel diseases (IBD), which affect 1.0 to 1.5 million
Americans, [1*] are a heterogeneous group of disorders resulting from continuous enteric
microbial antigenic stimulation of pathogenic T cell responses in individuals with genetic
defects in mucosal barrier function, innate bacterial killing or immunoregulation. [2*]
Altered microbial composition, defective clearance of bacteria and enhanced mucosal uptake
in Crohn’s disease (CD) and ulcerative colitis (UC) increase immune stimulation. CD and
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UC preferentially occur in areas of highest intestinal bacterial concentrations and fecal flow
sustains inflammation of CD. [3] Ciprofloxacin and metronidazole treat colonic CD and
experimental colitis in a number of rodent models. [4] This review describes evidence of the
roles of commensal bacteria in the pathogenesis of IBD in articles published January 2007 to
December 2008.
Defective bacterial killing in Crohn’s disease
Pathophysiologic similarities between CD and chronic granulomatous diseases associated
with defective phagocyte function, polymorphisms of genes regulating clearance of
intracellular pathogens and observed defects in innate antimicrobial function have led to the
hypothesis that a subset of CD is caused by defective clearance of commensal, opportunistic
or pathogenic bacteria with subsequent initiation of compensatory antibacterial effector T
cells that cause tissue damage. [2*, 5] Secretion of both α- and β-defensins is defective in
CD, [6, 7] with decreased Paneth cell α-defensin production due to reduced expression of
Tcf-4, a WNT-signaling pathway transcription factor. [8] The truncation mutation of NOD2,
which is an intracellular receptor for the peptidoglycan component muramyl dipeptide,
results in decreased ileal α-defensin production. [6] Furthermore, NOD2 deficient mice
exhibit decreased α-defensin defcr-4, [9] while deletion of the autophagy gene ATG16L1 or
the endoplasmic reticulum stress protein XBP-1 results in Paneth cell morphologic changes
and decreased expression of antimicrobial peptides. [10**, 11*] CD is associated with
genetic polymorphisms of at least 2 autophagy pathway components, ATG16L1 and IRGM,
which, like NOD2 and NCF2, regulate intracellular bacterial killing. [12*, 13*, 14*]
Decreased antimicrobial peptide secretion could lead to overgrowth, increased mucosal
adherence and translocation of commensal bacteria, while defective clearance of invasive or
phagocytosed bacteria promotes persistence of viable intracellular bacteria. (Figure 1.) Both
mechanisms could result in excessive antigenic stimulation of pathogenic TH1/TH17 cells,
chronic granulomatous inflammation and susceptibility to infection by traditional and
opportunistic pathogens.
Microbial pathogens
Comprehensive culture and molecular-based analyses of the microbiota of IBD patients fail
to identify consistent enrichment of individual pathogenic species in IBD tissues. However,
bacterial pathogens continue to reap attention because of similarities between CD, UC and
enteric infections and the hope of finding a cure analogous to Helicobacter pylori in peptic
ulcers.
Mycobacterium avium subspecies paratuberculosis—Mycobacterium avium
subspecies paratuberculosis (MAP) causes spontaneous granulomatous enterocolitis
(Johne’s disease) with diarrhea and wasting in ruminants, making this obligate intracellular
pathogen a credible etiologic agent of Crohn’s disease. [15] After considerable investigation,
the link between MAP and CD remains neither substantiated nor invalidated. Many
investigators continue to measure the MAP-specific insertion element IS900 DNA in the
tissue and/or blood of IBD patients using polymerase chain reaction (PCR) with mixed
results. (Table 1.)
A study conducted at the University of Colorado reported no detectable MAP DNA in 190
tissue samples from CD, UC and control patients. [16**] Baumgart et al similarly reported
lack of detectable IS900 DNA in ileal CD biopsies. [17**] Contradictory results were
reported by Scanu et al, who detected MAP DNA in 87% of CD tissues and 15% of controls
in a small cohort. [18] Results are also inconsistent in PCR assays for MAP DNA in blood
samples. [20–22]
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One recent, blinded study offered an alternative method to PCR for identifying MAP in CD
patients. [25] Coded, paraffin-embedded surgical resections from CD and control subjects at
two centers subjected to acid-fast staining and rRNA in situ hybridization (ISH) for MAP
were visualized with oil-immersion microscopy. Both methods provided positive results in
10/17 CD subjects, (59%, CI: 36–78), contrasted with 5/35 control subjects, (OR for CD
versus controls = 8.6, p = 0.002). Agreement between the two methods was good, but the
time-consuming ISH probes could not discriminate between mycobacterial subspecies.
Defective bacterial killing by innate immune cells could increase risk of infection by
intracellular pathogens. Two recent studies showed no association between MAP and NOD2
mutations. No significant association was seen in New Zealand CD patients for carriage of
heterozygous or homozygous NOD2 mutations and MAP status, [21] or between MAP
serologies and NOD2 polymorphisms in a large, population-based study in Manitoba. [26*]
A recent epidemiologic report also failed to support exposure to MAP by contaminated milk
or water. [27*] Furthermore, consumption of pasteurized milk and fruit was associated with
a reduced risk of CD, whereas meat intake was associated with an increased risk. Finally, a
well-designed, 2 year prospective trial of clarithromycin, rifabutin, and ethambutol failed to
show sustained clinical response in CD patients. [28*]
Recent studies possibly linking MAP to pathogenic mechanisms of CD fuel the ongoing
debate. 235 patients with CD, UC, irritable bowel syndrome (IBS) and no known disease
were tested for presence of MAP IS900 DNA and cytokine secretion in intestinal biopsy
samples. [23] Greater TNF levels correlated with the presence of MAP in CD patients (p <
0.05). However, there was no correlation of MAP with IL-2, IL-12, IL-10, and IFN-γ
secretion. A separate study linked MAP to active CD via IL-4 and IL-2 cytokine profiles in
peripheral blood with no differences in IFN-γ or TNF levels. [24]
Finally, MAP was recently reported to induce experimental colitis in gnotobiotic IL-10−/−
mice. [29] Germ-free IL-10−/− mice receiving a single oral dose of milk containing 10^4
CFU of live MAP obtained from a CD patient developed more severe and aggressively
progressive colitis, had higher serum amyloid A, IFN-γ and TNF levels, and lost more
weight than did IL-10−/− mice that received heat-killed MAP.
Despite continued suggestions of a link between MAP and IBD, it remains doubtful that
MAP is the causative agent of most CD patients, although infection of a subset of patients
with intracellular killing defects caused by ATG16L1, IGRM or NCF4 needs to be
investigated. CD-related NOD2 polymorphisms do not appear to be risk factors for MAP
infection.
Functional changes in Escherichia coli: Darfeuille-Marchaud reported that adherent/
invasive E. coli (AIEC) that persist within macrophages and epithelial cells selectively
colonize the ileum of CD patients. [30, 31] At least 2 separate groups have confirmed these
observations. Baumgart et al demonstrated AIEC in the ileum of CD patients, documented in
vivo mucosal adherence with fluorescent in situ hybridization (FISH) and identified AIEC
virulence factors common to uropathic E. coli strains and E. coli strains isolated from boxer
dogs with spontaneous granulomatous colitis. [17**] In a separate study, E. coli comprised
99% of invasive bacterial isolates in mucosal biopsies of CD patients as opposed to 42% in
UC patients and 2% in normal controls. [32*] A prototypic AIEC strain, LF82, induced in
vitro granulomas using blood-derived mononuclear cells. [33*] Serum antibodies directed
against E. coli outer membrane protein C (OmpC) are present in 37–55% of patients with
CD, in contrast to ≤ 5% of UC patients and subjects without IBD. High serum reactivity to
E. coli OmpC is associated with severe CD with longer disease duration, frequent disease
progression, small bowel involvement, and increased resections. [34]
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Mechanisms of epithelial adherence and invasion of AIEC are being elucidated. Studies
utilizing isogenic mutants of LF82 that lack OmpC and other genes suggest that increased
expression of OmpC, particularly at high osmolarities reflecting the GI tract, and/or
induction of the σE regulatory pathway promote adherence and invasion of epithelial cells
by LF82 independent of the transcriptional regulator OmpR. [35*]
Flagellin is necessary for LF82’s ability to exacerbate DSS-induced murine colitis. [36*]
Nonflagellated LF82 mutants behaved like the nonpathogenic E. coli strain K-12 in this
model. An LF82 mutant lacking dsbA, a gene that encodes a periplasmic oxidoreductase that
determines virulence for several pathogens, expressed neither flagella nor type 1 pili, and
displayed decreased survival ability. [37*] In contrast, decreased epithelial adhesion and
invasion of the LF82 OmpC and OmpR mutants were not associated with decreased
expression of flagella and type 1 pili. In a separate study, E. coli 083:H1 was dependent
upon flagellin for its adherent and invasive phenotype. [38*] Increased expression of
carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), which acts as a
receptor for AIEC, by ileal epithelial cells in active Crohn’s disease may mediate increased
mucosal adherence of AIEC. [39*] Increased CEACAM6 expression by cultured colonic
epithelial cells after IFN-γ or TNF stimulation and after exposure to LF82 indicate that
AIEC may promote its own colonization.
Monocytes from CD patients carrying homozygous or heterozygous NOD2 polymorphisms
displayed reduced secretion of IL-1β, IL-6, and IL-10 to LF82 in vitro compared with
monocytes from CD patients without NOD2 polymorphisms. [40**] TLR4 polymorphisms
did not influence monocyte response. In preliminary studies, we showed that macrophages
from NOD2 deficient mice display defective clearance of a murine AIEC strain with
prolonged secretion of IL-12/23 p40 and TNF. [41] These findings demonstrate the
importance of genetically programmed host immune responses to disease-related bacteria in
the pathogenesis of CD.
Enteric pathogens as environmental triggers: A case-control study examining medical
records of 3,019 U.S. soldiers who developed IBD and 11,646 matched controls compared
data using a conditional logistic regression model to determine that a single episode of
infectious gastroenteritis increased the risk of IBD, (OR: 1.40, CI: 1.19–1.66). [42] These
results suggest that a self-limited enteric pathogen could trigger IBD, possibly by breaking
the mucosal barrier and initiating an early inflammatory response in a genetically
susceptible host with immunoregulatory abnormalities. [2*] Clostridium difficile can
reactivate quiescent IBD [43*] and induce acute experimental epithelial injury by Fas-
mediated apoptosis. [44] Likewise enterotoxigenic Bacteroides fragilis can induce
experimental colitis and IL-17 production. [45] A role for non-pylori Helicobacter in IBD
pathogenesis is unlikely based on detection of species-specific serum antibodies in only
6/137 IBD patients. [46]
Dysbiosis
Recent studies in rodents confirm that bacterial composition changes with colonic
inflammation and/or infection. [47] Use of molecular techniques is clarifying changes in the
composition of the mucosally associated and fecal microbiota in patients with CD and UC
and vastly extending previous culture based studies. (Table 2.)
Examining DNA libraries of mucosal-associated microbiota, which may be more relevant
than the fecal microbiota to the pathogenesis of IBD, reveals that patients with CD and UC
have decreased complexity of commensal bacteria. [16**] Most notably, members of the
phyla Bacteroidetes and Firmicutes are decreased in CD and UC. These organisms promote
GI health in multiple ways. [59] Reduced Faecalibacterium prausnitzii, a major member of
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the family Firmicutes, in CD patients [16**, 50**] was confirmed and associated with a
higher risk of post-resection recurrence of ileal CD. [49**] In vitro peripheral blood
mononuclear cell stimulation by F. prausnitzii decreased IL-12 and IFN-γ production and
stimulated secretion of IL-10. Oral administration of either live F. prausnitzii or its
supernatant reduced the severity of TNBS colitis and corrected the associated dysbiosis. In
parallel, the abundance of E. coli is increased in IBD, particularly the B2+D phylogenetic
group. [17**, 48*] E coli isolated from CD patients express uropathic-like virulence factors
that are postulated to facilitate mucosal invasion. [17**] The number of mucosal E. coli in
situ correlates with the severity of ileal disease and invasive E. coli are restricted to inflamed
mucosa. Compositional changes of the microbiota (dysbiosis) in IBD subsets may contribute
to disease severity, since abnormal microbiotas correlated with the occurrence of abscesses
in CD patients, and IBD patients with dysbiosis underwent surgery at a younger age than
those with normal microbiotas. [16**] Finally, fecal and mucosally associated microbial
communities of patients with CD and UC are consistently less diverse with increased
temporal instability. [16**, 53*, 54*, 55*, 56*]
Nonpathogenic bacteria can cause colitis in hosts with immunoregulatory and mucosal
barrier deficits. When germ-free IL-10−/− and wild type (WT) mice were inoculated with
nonpathogenic E. faecalis and/or E. coli, dual-associated IL-10−/− (but not WT) mice
developed aggressive TH1/TH17-mediated colitis within 3 weeks that progressed to severe
pancolitis by 7 weeks. [60*] A separate study revealed that uptake of nonpathogenic E. coli
strains K-12 and HB101 by specialized follicle-associated epithelial cells overlying Peyer’s
patches, (the site of the earliest observable microscopic lesions of recurrent CD), is
increased in CD patients, but not in UC subjects. [61*] Increased E. coli localized within
dendritic cells of CD mucosa correlated with augmented tissue release of TNF.
Metabolic products of the microbiota have important effects on mucosal epithelial cell and
immune function. [2*] Butyrate and other short-chain fatty acids are the primary metabolic
substrates of colonocytes, with rectal epithelial cells dependent on this fuel source, while
hydrogen sulfide (HS), nitric oxide (NO) and serine proteases produced by a subset of
commensal microbiota can injure epithelial cells and matrix components. [62*] HS and NO
block butyrate metabolism and could lead to a state of epithelial starvation relevant to the
pathogenesis of UC.
Probiotics
Animal models and human studies suggest that therapeutically manipulating the balance
between beneficial and detrimental intestinal bacterial species can influence health and
disease. [63] Use of probiotics, (viable, nonpathogenic microorganisms that exert health
benefits beyond basic nutrition), to shift this balance to favor protective species and treat
IBD, has been extensively reviewed [63, 64*, 65, 66, 67*], yet the role for probiotics in
treating CD and UC remains undetermined because most trials are underpowered and
therefore not definitive.
In a TNBS colitis model, oral Lactobacillus acidophilus, Bifidobacterium lactis, and
Lactobacillus casei reduced intestinal inflammation. [68] L. casei had more modest
protection than the other probiotic species, yet in a separate in vitro study, live L. casei
decreased TNF, IFN-γ, IL-2, IL-6, IL-8, and CXCL1 secretion by explanted CD mucosa
and counteracted the proinflammatory effects of commensal E. coli ATCC 35345. [69] This
and other studies emphasize host-specific responses to probiotics. Other probiotic species
control aberrant immune responses in intestinal tissue. Bifidobacterium bifidum (BGN4)
prevented colitis in a murine CD4+ CD45RBhigh T cell transfer model. [70*] Lactobacillus
gasseri expressing manganese superoxide dismutase ameliorated colitis in IL-10−/− mice,
demonstrating the therapeutic potential of recombinant bacteria engineered to secrete
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biologically active molecules. [71*] Orally administered Lactobacillus suntoryeus HY7801
ameliorated TNBS-induced colitis, decreased colonic IL-1β, IL-6, and TNF expression and
inhibited TLR4-linked NFκB activation. [72*] Bifidobacterium-fermented milk enhanced
IL-10 production in peripheral blood mononuclear cells from UC patients and inhibited IL-8
secretion by intestinal epithelial cells. [73] Lactobacillus rhamnosus GR-1 and Lactobacillus
reuteri RC-14 fed in yogurt to IBD patients had peripheral blood anti-inflammatory effects.
In an in vitro study, L. reuteri potently suppressed human TNF production by
lipopolysaccharide-activated monocytes and monocyte-derived macrophages from children
with CD in a strain-dependent manner by inhibiting activation of MAP kinase-regulated c-
Jun and the transcription factor AP-1. [74*]
Several groups have investigated the probiotic combination VSL#3 as a treatment for IBD
based on its ability to maintain remission in relapsing pouchitis. [75, 76] This combination
of 4 live Lactobacillus strains, (L. casei, bulgaricus, plantarium and acidophilus), 3 live
Bifidobacterium strains, (B. longum, breve and infantis), and 1 live Streptococcus strain,
(thermophilus), dose-dependently ameliorated DSS-induced colitis in weanling rats. [77] In
a small (N=18) open-label study, VSL #3 induced remission in 56% of pediatric patients
with mild to moderate UC. 6% showed a response, and 39% had no response or did worse
with treatment. [78*] Daily oral VSL #3 significantly reduced the pouchitis disease activity
index and expanded the number of mucosal regulatory T cells following colectomy with
ileal pouch anal anastomosis. [79*] Two components of VSL #3, B. longum and B. breve, in
combination with the prebiotic psyllium, were well-tolerated at high doses and induced
remission in 6/10 patients with Crohn’s disease who had failed a regimen of
aminosalicylates and prednisolone. [80*]
Similar to Sokol et al’s studies with F. prausnitzii, [49**] an Israeli group isolated and
characterized a new putative protective bacterial species, Enterococcus durans, from the
fecal microbiota of a healthy human vegetarian. [81*] In a DSS model of colitis, oral
administration of E. durans significantly ameliorated colitis compared to controls and mice
fed Lactobacillus delbrueckii. To properly note negative studies, oral administration of
Lactobacillus johnsonii failed to prevent early postoperative endoscopic recurrence of CD
12 weeks after ileo-caecal resection. [82]
To date, probiotics appear to be more effective in preventing relapse of UC and pouchitis,
with poor results in CD. Examining F. prausnitzii in preventing postoperative recurrence of
CD will be quite interesting and could lay the foundation for targeted correction of dysbiotic
microbiota in IBD. Use of prebiotics, which are poorly absorbed oligosaccharides that
stimulate growth and metabolic activity of beneficial microbiota, could be a low cost,
nontoxic strategy to correct dysbiosis in IBD patients.
Conclusions and future directions
There remains no evidence that MAP is a causative agent in the pathogenesis of IBD. A
more likely scenario involves specific E. coli strains and other species with virulence factors
that allow them to adhere to and invade epithelial cells and persist within macrophages.
These strains could be viewed as opportunistic pathogens in genetically susceptible hosts
with innate killing, mucosal barrier or immunoregulatory defects, with no disease induced in
normal hosts. Identifying and then eliminating these strains, blocking expression of their
virulence factors or altering their metabolism and identifying host susceptibility factors
could be essential keys to treating IBD. Likewise, identifying changes in microbiota
composition, gene expression and metabolic profiles in different IBD patient subsets using
rapidly evolving molecular tools will provide important new insights into the pathogenesis
and novel treatment of IBD using the example of F. prausnitzii. [49**] Meanwhile, using
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probiotics and prebiotics to enhance concentrations of beneficial species remains promising,
although clinical trials lack statistical power due to small numbers. Treatments need to be
individualized based on compositional alterations in patient subsets. Understanding bacterial
and host mutalistic interactions will determine success in this area.
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Figure 1. Defective containment of commensal bacteria in IBD
Crohn’s disease genes that affect bacterial killing result in defective containment of
commensal bacteria. NOD2 polymorphisms result in defective α-defensin production and
clearance of intracellular bacteria. Overgrowth of mucosal bacteria occurs with defective
secretion of antimicrobial peptides (NOD2 and ATG16L1 polymorphisms) or secretory IgA.
Inefficient killing of phagocytosed bacteria (NOD2, ATG16L1, NCF4 and IGRM
polymorphisms) results in persistent intracellular bacteria and ineffective clearance of
bacterial antigens. Increased mucosal permeability leads to overwhelming exposure of
bacterial TLR ligands and antigens that activate pathogenic innate and T-cell immune
responses. Modified from ref 2 and used with permission of Elsevier Publishing Company.
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